Want to see BOLT full AI Analyst Report?
Bolt Biotherapeutics (BOLT) Stock Statistics & Valuation Metrics
Total Valuation
Bolt Biotherapeutics has a market cap or net worth of $12.69M. The enterprise value is $10.33M.
- Market Cap
- $12.69M
- Enterprise Value
- $10.33M
Share Statistics
Bolt Biotherapeutics has 1,926,345 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,926,345
- Owned by Insiders
- 7.62%
- Owned by Institutions
- 6.23%
Financial Efficiency
Bolt Biotherapeutics’s return on equity (ROE) is -1.26 and return on invested capital (ROIC) is -67.72%.
- Return on Equity (ROE)
- -1.26
- Return on Assets (ROA)
- -0.59
- Return on Invested Capital (ROIC)
- -67.72%
- Return on Capital Employed (ROCE)
- -0.72
- Revenue Per Employee
- 334.57K
- Profits Per Employee
- -1.45M
- Employee Count
- 23
- Asset Turnover
- 0.14
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Bolt Biotherapeutics is -0.41. Bolt Biotherapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.41
- PS Ratio
- 2.70
- PB Ratio
- 0.88
- Price to FCF
- -0.40
- Price to Operating Cash Flow
- -0.35
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of 7.70M and earned -33.38M in profits. Earnings per share was -17.85.
- Revenue
- 7.70M
- Gross Profit
- 6.20M
- Operating Income
- -34.63M
- Pretax Income
- -33.38M
- Net Income
- -33.38M
- EBITDA
- -32.09M
- Earnings Per Share (EPS)
- -17.85
Cash Flow
In the last 12 months, operating cash flow was -31.45M and capital expenditures -85,000, giving a free cash flow of -31.54M billion.
- Operating Cash Flow
- -31.45M
- Free Cash Flow
- -31.54M
- Free Cash Flow per Share
- -18.65
Dividends & Yields
Bolt Biotherapeutics pays an annual dividend of $0.09, resulting in a dividend yield of ―
- Dividend Per Share
- $0.09
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -262.78%
- Earnings Yield
- -272.87%
Stock Price Statistics
- Beta
- 0.37
- 52-Week Price Change
- 15.01%
- 50-Day Moving Average
- 4.14
- 200-Day Moving Average
- 4.46
- Relative Strength Index (RSI)
- 75.20
- Average Volume (3m)
- 242.12K
Important Dates
Bolt Biotherapeutics upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- Aug 29, 2014
Financial Position
Bolt Biotherapeutics as a current ratio of 3.59, with Debt / Equity ratio of 86.62%
- Current Ratio
- 3.59
- Quick Ratio
- 3.59
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.35
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Bolt Biotherapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Bolt Biotherapeutics EV to EBITDA ratio is -0.75, with an EV/FCF ratio of -0.66.
- EV to Sales
- 4.42
- EV to EBITDA
- -0.75
- EV to Free Cash Flow
- -0.66
- EV to Operating Cash Flow
- -0.66
Balance Sheet
Bolt Biotherapeutics has $17.60M in cash and marketable securities with $21.62M in debt, giving a net cash position of -$4.03M billion.
- Cash & Marketable Securities
- $17.60M
- Total Debt
- $21.62M
- Net Cash
- -$4.03M
- Net Cash Per Share
- -$2.09
- Tangible Book Value Per Share
- $7.48
Margins
Gross margin is 95.68%, with operating margin of -623.04%, and net profit margin of -611.47%.
- Gross Margin
- 95.68%
- Operating Margin
- -623.04%
- Pretax Margin
- -611.47%
- Net Profit Margin
- -611.47%
- EBITDA Margin
- -591.91%
- EBIT Margin
- -611.47%
Analyst Forecast
The average price target for Bolt Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- 12.79%
- EPS Growth Forecast
- 37.93%
Scores
- Smart Score
- ―
- AI Score
- 49
